CINCOR PHARMA, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • December 17th, 2021 • CinCor Pharma, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is dated as of , 20 , and is between CinCor Pharma, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • December 17th, 2021 • CinCor Pharma, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of September 22, 2021, by and among CinCor Pharma, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof each of which is referred to in this Agreement as an “Investor”.
License Agreement This Agreement is entered into with effect as of the Effective Date (as defined below) by and betweenLicense Agreement • December 17th, 2021 • CinCor Pharma, Inc. • Pharmaceutical preparations
WHEREAS, Roche has discovered and has conducted certain research and development related to, and possesses certain proprietary intellectual property with respect to the small molecule aldosterone synthase inhibitors (ASI), also known as RO6836191 (AS1(1)) [***] (“Compound(s)” as further defined below); and
AMENDED AND RESTATED MANAGEMENT SERVICES AGREEMENTManagement Services Agreement • December 17th, 2021 • CinCor Pharma, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED MANAGEMENT SERVICES AGREEMENT (this “Agreement”) is made effective as of April 16, 2020 (the “Effective Date”), by and between CinCor Pharma, Inc., a Delaware corporation (“CinCor”), and CinRx Pharma, LLC, an Ohio limited liability CinCor (“CinRx”).
